49. Systemic lupus erythematosus
827 clinical trials,   638 drugs   (DrugBank: 168 drugs),   108 drug target genes,   191 drug target pathways

Searched query = "Systemic lupus erythematosus", "SLE"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
8 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR-INR-17011495
2017-05-252017-05-26The efficacy and safety of metformin hydrochloride combined with atorvastatin in the treatment of primary mild to moderate systemic systemic lupus erythematosusThe efficacy and safety of metformin hydrochloride combined with atorvastatin in the treatment of primary mild to moderate systemic systemic lupus erythematosus Primary mild to moderate systemic systemic lupus erythematosusImmunomodulatory treatment group:The level of SELSNA-SLEDAI was evaluated at week 4, week 12 and week 24, the BILAG table, the SLE lesion index, and the SLE damage index were measured at 4 weeks, 12 weeks and 24 weeks. The levels of Th17, Treg and Th17 / Treg were measured.;Leflunomide treatment group:Leflunomide tablets 10m, 1 times / day, orally. The SELSNA-SLEDAI score table, BILAG worksheet, SLE damage index score were assessed at week 4, week 12 and week 24, and serum Th17, Treg and Th17 / Treg ratios were measured.;Immunomodulatory treatment group and Leflunomide treatment group :0 weeks to give prednisone acetate tablets 0.5-1mg / kg.d (or patients can choose to take the same dose of methylprednisolone tablets), 4 weeks after the beginning of the dose by 2 weeks to reduce the regular dose of 10% Reduction to prednisone acetate tablets 10mg / day to maintain.;Immunomodulatory treatment group and Leflunomide treatment group:All patients without contraindications plus hydroxychloroquine tablets 0.2,2 / day, orally; and according to the condition plus calcium (800-1200mg / day), vitamin D (200-800IU / day) and other treatment.;The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and TechnologyNULLRecruitingBothImmunomodulatory treatment group:15;Leflunomide treatment group:15;Immunomodulatory treatment group and Leflunomide treatment group :30;Immunomodulatory treatment group and Leflunomide treatment group:30;China
2NCT03155477
(ClinicalTrials.gov)
June 10, 201613/5/2017Effect Of Curcuma Xanthorrhiza and Vitamin D3 Supplementation in SLE Patients With Hypovitamin DEffect Of Curcuma Xanthorrhiza Supplementation In Systemic Lupus Erythematosus Patients (SLE) With Hypovitamin D Which Were Given Vitamin D3 Towards Disease Activity (SLEDAI), Interleukin-6 (IL-6) And Tumor Growth Factor-ß1 (TGF-ß1) SerumSLEDietary Supplement: Cholecalciferol and C. Xanthorrhiza;Dietary Supplement: Cholecalciferol and placeboSaiful Anwar HospitalNULLCompleted18 Years45 YearsFemale39N/ANULL
3NCT01709474
(ClinicalTrials.gov)
June 201316/10/2012Vitamin D3 Treatment in Pediatric Systemic Lupus ErythematosusVitamin D3 Effects on Immune Function in Pediatric Systemic Lupus Erythematosus (SLE)Systemic Lupus ErythematosusDrug: Vitamin D3 6000 IU;Drug: Vitamin D3 400 IUNational Institute of Allergy and Infectious Diseases (NIAID)Autoimmunity Centers of ExcellenceTerminated5 Years20 YearsAll7Phase 2United States
4NCT01911169
(ClinicalTrials.gov)
June 201122/7/2013Vitamin D to Improve Endothelial Function in SLEVitamin D Repletion to Improve Endothelial Function in Lupus PatientsAtherosclerosis;Systemic Lupus ErythematosusDrug: CholecalciferolMedical University of South CarolinaNULLCompleted18 Years80 YearsAll9Phase 2United States
5NCT01425775
(ClinicalTrials.gov)
April 201018/8/2011The Effect of Vitamin D Supplementation on Disease Activity Markers in Systemic Lupus Erythematosus (SLE)Systemic Lupus ErythematosusDrug: vitamin D 25(OH)D;Other: PlaceboFaculty of Medicine, University of AlexandriaNULLCompleted18 Years60 YearsBoth248N/AEgypt
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT01413230
(ClinicalTrials.gov)
January 201024/6/2011Vitamin D Supplementation in Systemic Lupus ErythematosusEvaluation of Immunologic Response After Vitamin D Supplementation in Patients With Systemic Lupus ErythematosusVitamin D DeficiencyDrug: cholecalciferolAssistance Publique - Hôpitaux de ParisNULLCompleted18 YearsN/ABoth20N/AFrance
7NCT00710021
(ClinicalTrials.gov)
November 20081/7/2008Vitamin D3 in Systemic Lupus ErythematosusEffect of Vitamin D3 on the IFN Alpha Signature in Patients With Systemic Lupus Erythematosus (ALE02)Systemic Lupus Erythematosus;SLE;LupusDrug: Vitamin D3;Drug: Vitamin D3 placeboNational Institute of Allergy and Infectious Diseases (NIAID)Autoimmunity Centers of ExcellenceCompleted18 YearsN/AAll57Phase 2United States
8NCT00418587
(ClinicalTrials.gov)
December 20064/1/2007Vitamin D Therapy in Patients With Systemic Lupus Erythematosus (SLE)Phase 1 Study of Vitamin D Therapy in Patients With Systemic Lupus Erythematosus (SLE)Systemic Lupus ErythematosusDrug: CholecalciferolMedical University of South CarolinaAmerican College of Rheumatology Research and Education Foundation;National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Completed18 Years85 YearsAll18Phase 1United States